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Abstract
Background: Epidermal growth factor receptor inhibitor therapy is now approved for treatment of metastatic
colorectal carcinomas (CRC) in patients with tumors lacking KRAS mutations. Several procedures to detect KRAS
mutations have been developed. However, the analytical sensitivity and specificity of these assays on routine
clinical samples are not yet fully characterised.
Methods: The practical aspects and clinical applicability of a KRAS-assay based on Pyrosequencing were evaluated
in a series of 314 consecutive CRC cases submitted for diagnostic KRAS analysis. The performance of
Pyrosequencing compared to allele-specific, real-time PCR was then explored by a direct comparison of CE-IVD-
marked versions of Pyrosequencing and TheraScreen (DxS) KRAS assays for a consecutive subset (n = 100) of the
314 clinical CRC samples.
Results: Using Pyrosequencing, 39% of the 314 CRC samples were found KRAS-mutated and several of the
mutations (8%) were located in codon 61. To explore the analytical sensitivity of the Pyrosequencing assay,
mutated patient DNA was serially diluted with wild-type patient DNA. Dilutions corresponding to 1.25-2.5% tumor
cells still revealed detectable mutation signals. In clinical practice, our algorithm for KRAS analysis includes a
reanalysis of samples with low tumor cell content (< 10%, n = 56) using an independent assay (allele-specific PCR,
DxS). All mutations identified by Pyrosequencing were then confirmed and, in addition, one more mutated sample
was identified in this subset of 56 samples. Finally, a direct comparison of the two technologies was done by re-
analysis of a subset (n = 100) of the clinical samples using CE-IVD-marked versions of Pyrosequencing and
TheraScreen KRAS assays in a single blinded fashion. The number of samples for which the KRAS codon 12/13
mutation status could be defined using the Pyrosequencing or the TheraScreen assay was 94 and 91, respectively,
and both assays detected the same number of codon 12 and 13 mutations.
Conclusions: KRAS mutation detection using Pyrosequencing was evaluated on a consecutive set of clinical CRC
samples. Pyrosequencing provided sufficient analytical sensitivity and specificity to assess the mutation status in
routine formalin-fixed CRC samples, even in tissues with a low tumor cell content.
Background
Targeting of epidermal growth factor receptor (EGFR) with
the monoclonal antibodies cetuximab or panitumumab pre-
vents activation of downstream signalling molecules.
Thereby cellular events such as proliferation, migration and
survival are affected. Anti-EGFR therapy is recommended
for patients with refractory metastatic colorectal cancer
(mCRC) and is currently evaluated in clinical studies as a
first line therapy in mCRC. However, activating somatic
point mutations in Kirsten RAS (KRAS) are strongly asso-
ciated with resistance to anti-EGFR therapy and are present
in approximately 40% of colorectal tumors [1-12]. Therefore,
treatment is only approved for patients harbouring a tumor
with a wild-type (wt) KRAS gene. Consequently, robust,
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required to stratify patients eligible for anti-EGFR therapy.
Specific mutations in codon 12, 13 or 61 of the KRAS gene
convert the gene into an active oncogene [13]. Mutations in
codon 12 or 13 are the most frequent alterations in KRAS
and represent more than 90% of all mutations. Analyses of
KRAS in CRC clinical trials have therefore focused on these
codons when relating KRAS mutational status to objective
response or survival during EGFR inhibitor therapy. Despite
being described as an activating KRAS mutation in vitro,t h e
frequency of codon 61 mutations in human tumors is gener-
ally reported as low [2,14-18], and the clinical impact of
these mutations is still under discussion [19,20].
The Pyrosequencing technology [21] has an analytical
sensitivity for detection of mutations that is superior to
that of Sanger (dideoxy) sequencing. Several in-house Pyr-
osequencing assays for detection of KRAS mutations in
codon 12, 13 and 61 have been developed [12,14,22,23].
However, in a clinical setting there are several challenges
when performing mutation analysis on DNA from routi-
nely formalin-fixed, paraffin-embedded (FFPE) tissue sam-
ples. These include suboptimal quality of DNA due to
formalin fixation, low tumor cell content in tumor tissues
with abundant inflammatory cells, and insufficient starting
material, e.g. minimal biopsy fragments. The practical
aspects and efficiency of the CE-IVD-marked Pyrosequen-
cing kit for analysis of KRAS mutations have until now not
been evaluated in a clinical setting.
The TheraScreen kit (DxS Ltd, Manchester, UK) is a
well-established CE-IVD-marked kit for diagnostic ana-
lysis of KRAS mutational status [24]. The DxS technol-
ogy combines allele-specific amplification with real-time
PCR for analysis of seven mutations in codons 12 and
13. With high quality DNA this method has the poten-
tial to detect ≤ 1% mutant alleles in DNA from a tumor
tissue. However, this level of sensitivity is difficult to
obtain in most diagnostic FFPE samples [25]. The DxS
technology was used in many of the retrospective stu-
dies that evaluated the response to anti-EGFR therapy in
relation to KRAS mutation status [4,26,27].
The aims of the present study were: (i) to describe the
KRAS mutation spectrum in a consecutive series of CRC
specimens (n = 314) referred to our laboratory for KRAS
mutation analysis during the last two years; (ii) to evaluate
the performance of Pyrosequencing compared to allele-
specific PCR (DxS) on the samples (n = 56) that originated
from tissues with a low tumor cell count; and (iii) to evalu-
ate the new CE-IVD-marked versions of these techniques
on a selected subset (n = 100) of the specimens.
Methods
Patient material
From January 2008 to June 2009, 314 consecutive FFPE
CRC patient tissues were subjected to KRAS mutation
analysis after a histological confirmation of adenocarci-
noma and presence of tumor cells in haematoxylin-
eosin-stained slides. In addition, the tumor cell fraction
was estimated and, when possible, tissue samples were
manually microdissected with a scalpel to enrich for
tumor cells before DNA extraction. The project was
conducted in compliance with the Helsinki Declaration.
The patient samples were used in accordance with the
Swedish Biobank Legislation and Ethical Review Act
(approval by Uppsala Ethical Review Board, reference
number: 2004:M-281 and 2009-224), including appropri-
ate procedures for informed consent.
DNA extraction
D e p e n d i n go nt h es i z eo ft h et i s s u es a m p l e ,o n et ot e n
sections (10 μmt h i c k )f r o mt h eF F P Eb l o c kw e r eu s e d
for genomic DNA extraction in an EZ1 workstation
using the EZ1 DNA tissue kit and EZ1 DNA paraffin
section card (QIAGEN GmbH, Hilden, Germany)
according to the manufacturer’si n s t r u c t i o n s .T h e
quality and concentration of the extracted DNA was
determined using a NanoDrop instrument (Thermo
Scientific, Wilmington, DE).
Samples for the CE-IVD-marked PyroMark and
TheraScreen assay comparison
Of the 314 samples, a subset of 100 consecutive samples
was used for a direct comparison of the two CE-marked
assays. Sample inclusion criteria for this part of the
study were a DNA concentration of ≥10 ng/μla n da
total amount of 440 ng DNA remaining after the origi-
nal diagnostic KRAS analysis. The 100 samples were
analysed for mutations in codons 12 or 13 using both
methods in a single blind fashion. The sample code key
was broken after all analyses were completed.
Pyrosequencing analysis
The initial Pyrosequencing analysis of the 314 samples
was performed according to the manufacturer’sr e c o m -
mendations for PyroMark Q24 KRAS and PyroMark
Q24 KRAS v2.0 assays. Briefly, 2×10 ng of genomic
DNA were used for analyses of KRAS codons 12/13 and
61 in 2×25 μl PCR reactions. Twenty μlo fe a c hP C R
product was subjected to Pyrosequencing analysis using
Streptavidin Sepharose High Performance (GE Health-
care, Uppsala, Sweden), PyroMark Gold Q96 reagents,
PyroMark Q24 1.0.9 software, and a Q24 instrument
(QIAGEN). The mutation analysis using the CE-IVD-
marked PyroMark KRAS kit (QIAGEN) in the compara-
tive study of the 100 samples was performed according
to the PyroMark KRAS Kit handbook, version 1, June
2009. Briefly, 10 ng of genomic DNA was used for the
initial 25 μl PCR reaction for codon 12 and 13 mutation
analysis of each sample. Ten μl of the PCR product was
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thresholds for the mutational analysis were a required
peak height of 30 relative light units (RLU) for “passed”
quality and 10 RLU for “check” quality. Samples with an
initial “check” status, or with an indicated mutation sig-
nal of 2-5%, were subjected to a second round of analy-
sis performed in triplicates. In addition, samples that
failed the initial PyroMark KRAS analysis were subjected
to a second round of analysis.
Analysis using the DxS TheraScreen K-RAS Mutation Kit
The TheraScreen analysis (DxS Ltd, Manchester, UK) is
an allele-specific PCR-based technology with specific
primers for the seven most common KRAS codon 12
and 13 mutations. The assay screen for the following
mutations: 12 GCT (Ala), 12 GAT (Asp), 12 CGT (Arg),
12 TGT (Cys), 12 AGT (Ser), 12 GTT (Val), and 13
GAC (Asp). Mutation analysis was performed according
to instructions in the TheraScreen K-RAS Mutation Kit
manual, version DU001e, January 2009 on an ABI
PRISM® 7900HT SDS PCR instrument (Applied Biosys-
tems Inc., Foster City, CA). In total 8×15 ng genomic
DNA was used for the initial analysis of each sample.
The quality thresholds when using the TheraScreen K-
RAS Mutation Kit followed the recommendations in the
manual, e.g. samples with a control assay with a cycle
threshold (Ct) of 35 or higher should be rejected and
samples with a mutation signal of Ct ≥38 should be
scored as negative (wild-type).
DNA quality control analysis
Analysis of DNA quality for samples that gave subopti-
mal results in both assays was performed by a multiplex
PCR reaction (Specimen Control Size Ladder, InVivo-
Scribe Technologies, San Diego, CA) for amplification
of five different DNA targets (100, 200, 300, 400 and
600 basepairs), according to the manufacturer’si n s t r u c -
tions. Products were visualised by electrophoresis on a
2% agarose gel.
Results
Frequency and distribution of KRAS mutations
During 2008 and 2009, 314 CRC samples were referred
for KRAS mutation analysis to the Molecular Pathology
l a b o r a t o r ya tU p p s a l aU n i v e r s i t yH o s p i t a l .B yu s eo f
commercially available Pyrosequencing technologies
(PyroMark Q24 KRAS and Q24 KRAS v2.0), we were
able to assess the mutation status for codon 12/13 in
306 (97.5%) and codon 61 in 304 (96.8%) of the cases.
S e eF i g u r e1f o rr e p r e s e n t a t i v ep y r o g r a m sd e s c r i b i n g
mutations in codons 12, 13 and 61.
Point mutations in codon 12/13 were identified in 112
samples (37%). In total, eight variants of codon 12/13
mutations were found (Figure 2A). Consistent with
previous reports, the most common mutations were 12
GAT, 12 GTT and 13 GAC [1,2]. Beside the seven most
established mutations, one unusual codon 12 mutation
(GGT>TTT, Gly to Phe) was identified. Additionally, ten
mutations in codon 61 were detected that were mutually
exclusive with mutations in codon 12 or 13. All of these
mutations lead to amino acid substitutions in the KRAS
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Figure 1 KRAS analysis by Pyrosequencing.R e p r e s e n t a t i v e
examples of Pyrosequencing KRAS analyses of codons 12 and 13 (A-
D) and codon 61 (E-F). Codon 12, 13 wt (A); codon 13 mutation
GGC>GAC (B); codon 12 mutation GGT>GAT (C); codon 12 mutation
GGT>GAT in DNA from tissue with less than 10% tumor cells (D);
codon 61 wt (E), and codon 61 mutation (F).
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Page 3 of 9protein (Figure 2B). In conclusion, the total number of
samples with KRAS mutations was 122 (39%) of which 10
(8.2%) were located in codon 61 (Figure 2C).
Tumor cell content and analytical sensitivity
The high abundance of genetically normal parenchymal,
stromal and inflammatory cells in human tumor tissues
limits the likelihood to detect mutations in the cancer cells
[28]. Therefore, tumor cell fractions were routinely esti-
mated by a pathologist followed by manual microdissec-
tion of the tissues to enrich for tumor cells. The final
mean tumor cell fraction in all analysed samples were 25%
and only 11% of the samples exhibited ≥50% tumor cell
content. However, no correlation was observed between
tumor cell content and the ability to detect mutations by
Pyrosequencing (Figure 3A, B). KRAS mutations were
detected in many samples with a very low tumor cell
count (Figure 3B), and the frequency of KRAS codon 12 or
13 mutations in tissues with a low (< 10%) tumor cell
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Figure 2 Distributions of KRAS mutations.F r e q u e n c yo ft h e
detected KRAS codon 12 and 13 mutations (A). Distribution of
mutations detected in codon 61 (B). Relative distribution of KRAS
codon 12, 13 and 61 mutations (C).
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Figure 3 Tumor cell content. Estimated tumor cell content, after
manual microdissection, in colorectal cancer tissues from 314
consecutive patient samples subjected to KRAS mutation analysis.
Tumor cell content in wt samples (A) and in samples with a
detected codon 12 or 13 KRAS mutation (B).
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Page 4 of 9content (36% mutation rate) was similar to that of tissues
with ≥10% tumor cells (37% mutation rate).
Sensitivity of the Pyrosequencing mutation detection
The sensitivity of the commercially available Pyrose-
quencing assay to detect KRAS mutations in DNA
extracted from FFPE tissue has not been fully evaluated.
Therefore, DNA was extracted from a KRAS-mutated
patient tissue carefully reviewed to contain 40% tumor
cells, and serially diluted with wt patient DNA. The Pyr-
osequencing analysis of the samples show that dilutions
corresponding to 1.25-2.5% tumor cells had a low, but
still detectable, mutation signal (Figure 4). Similar
results were obtained using the TheraScreen K-RAS
Mutation kit (mutation detected down to 1.25% tumor
cells) consistent with the reported sensitivity of this
method (data not shown).
Our diagnostic algorithm for KRAS analysis includes
reanalysis of all samples with < 10% tumor cells using
an independent assay. Thus, samples with a low tumor
cell count (n = 56) were also analysed by a mutation
specific PCR method (TheraScreen K-RAS Mutation
kit). All codon 12/13 mutations detected by Pyrosequen-
cing were confirmed, and in three additional samples
indications of KRAS mutations were found. However, of
these three samples, only one met the formal analysis
criteria of the TheraScreen assay, i.e. that the real-time
PCR signal for a mutation had a Ct value below 38.
This sample had 5% tumor cells and a codon 12
GGT>GAT mutation.
Comparison of the CE-IVD-marked PyroMark and
TheraScreen K-RAS assays
When performing clinical KRAS analyses, some samples
will generate a borderline result due to low overall sig-
nal strength or a weak mutation signal. Validated assays,
w i t has t r i n g e n td e f i n i t i o no fat r u ep o s i t i v es i g n a l ,a r e
therefore essential. Since May 2009 there is a CE-
marked Pyrosequencing kit (PyroMark KRAS kit, QIA-
GEN) available for in vitro diagnostic use in Europe.
Therefore, we compared the performance of this new
Pyrosequencing kit with the CE-marked TheraScreen
K-RAS Mutation kit in a single blinded study protocol.
DNA aliquots from a consecutive subset (n = 100) of
the 314 CRC samples were analysed for KRAS mutations
in codons 12 and 13 using both methods, and inter-
preted according to the manuals regarding procedures
and criteria for positive and negative mutation results.
Eighty-nine of the 100 samples analysed with the
PyroMark KRAS kit passed the quality criteria in the
initial run. Four samples had an initial, and final, “failed”
status (signal strength below the defined limits). Because
of weak signal strength or indications of a KRAS muta-
tion signal, the remaining seven samples were reanalysed
in triplicates. After reanalysis, five of the samples passed
the quality criteria. Thus, the mutational status of
codons 12 and 13 could be defined for 94% of the sam-
ples by using this method.
With the CE-IVD-marked TheraScreen K-RAS Muta-
tion kit, the mutational status of 89 of the 100 samples
could be assessed in the initial analysis. Nine samples
were rejected due to a control Ct of ≥35. The remaining
two samples passed the quality criteria after reanalysis in
triplicate. Thus, the total nu m b e ro fs a m p l e sf o rw h i c h
the mutational status could be defined using this assay
was 91. Results of the failed, rejected, and reanalysed
samples from both methods are outlined in Table 1.
Of the 94 samples, for which the mutational status
could be defined using the PyroMark KRAS assay, 33
exhibited a KRAS mutation in codon 12 or 13. Similarly,
33 of the 91 passed samples in the TheraScreen muta-
tional analysis were KRAS-mutated. When the DNA
sample code was broken, 89 samples passed both assays
and had the same mutational status. Five samples
(DNA# 21, 37, 64, 67 and 89) failed the quality criteria
of both assays (Table 1). Four samples (DNA# 25, 30,
61 and 66), were rejected in the TheraScreen assay, but
could be defined as KRAS wt or codon 12 mutated
(DNA# 66) when analysed by Pyrosequencing. Conver-
sely, one sample (DNA# 93) gave inconclusive results in
the Pyrosequencing assay but was scored as KRAS wt by
DNA samples
Background /noise
5
15
25
4
0
%
2
0
%
1
0
%
5
%
2
.
5
%
1
.
2
5
%
0
%
Tumour cell content 
L
i
g
h
t
 
e
m
i
s
s
i
o
n
 
(
R
L
U
)
Figure 4 Evaluation of the sensitivity of the Pyrosequencing
technology for detection of KRAS mutations. DNA from a KRAS
codon 12 mutated tissue with a tumor cell content of 40% was
serially diluted in wt DNA. Each dilution was analysed in triplicate
by Pyrosequencing. The relative light units (RLU) for the mutation
signal are presented.
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Page 5 of 9the TheraScreen assay. Finally, DNA# 54 was defined as
12Val-mutated by TheraScreen analysis, but this muta-
tion could not be unequivocally confirmed in the Pyro-
Mark assay.
Evaluation of DNA quality in rejected samples
Eight of the nine samples with a “failed” or “check” sta-
tus due to low signal intensity in the PyroMark KRAS
analysis were also rejected in the TheraScreen analysis
due to a control Ct > 35 (Table 1). Hence, the quality of
the DNA in these samples was most likely sub-optimal.
To investigate why some samples gave suboptimal
results, ten samples were subjected to a multiplex PCR
amplification to obtain 100-600 basepair (bp) products
(Figure 5). None of the six samples with a “failed”
(DNA# 64, 67 and 89) or “check” (DNA# 25, 37 and 93)
status in the PyroMark KRAS analysis generated an
amplicon longer than 100 bp. Five of these samples
(DNA# 25, 37, 64, 67 and 89) also failed the quality cri-
teria in the TheraScreen analysis. Hence, most likely, a
high degree of DNA fragmentation contributes to the
failure to fulfil the quality control criteria of the assays
in these samples. For the remaining four DNA samples,
that passed in both assays, it was possible to amplify
300-400 bp fragments.
Discussion
Mutated RAS was first identified by its ability to trans-
form cell lines in DNA transfection experiments. It was
then concluded that the transforming ability was due to
activating point mutations resulting in an amino acid
substitution at codon 12, 13, or 61 [13,29,30]. However,
mutation analysis of codon 61, or rare mutations in
codon 12 or 13, were not included in the clinical studies
that lie behind the recommendation to use anti-EGFR
therapies only for KRAS wt metastatic CRC [31,32].
In our cohort of 314 colorectal cancer patients, 39%
(n = 122) of the samples were mutated in KRAS codon
12, 13 or 61. As expected, most mutations were located
in codon 12 or 13 (n = 112) and represented well-estab-
lished types of mutations in CRC [1]. One unusual
codon 12 mutation (GGT > TTT) was also identified.
This mutation has, to our knowledge, only been
reported three times [2,33-35]. The frequency of codon
61 mutations is generally believed to be low. However,
similar to a recent study [19], 8% (n = 10) of the
detected KRAS mutations in our cohort were located in
codon 61. Four of these result in a change of the wt glu-
tamic acid to histidine. In the infrequent, but highly
malignant, signet ring cell CRC KRAS codon 12 and 13
mutations are less frequent than in other CRC subtypes
[36]. Interestingly, more codon 61 histidine substitutions
than codon 12 or 13 mutations have been reported in
signet ring cell CRC [37]. Although the distribution and
relative frequencies of the mutation types can vary
Table 1 Failed, rejected, and reanalysed samples in the comparison of the PyroMark and TheraScreen K-RAS assays
DNA # PyroMark TheraScreen Comments
21 ND ND Pyro: Failed, repeated twice. DxS: Rejected, control Ct > 35
25 WT ND Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35
30 WT ND Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35
37 ND ND Pyro: Check, triplicate = inconclusive. DxS: Rejected, control Ct > 35
54 WT 12 GTT Pyro: Triplicate = wt. DxS: 12 GTT mutation
61 WT ND DxS: Rejected, control Ct > 35
64 ND ND Pyro: Failed. DxS: Rejected, control Ct > 35
66 12 GAT ND Pyro: Check, triplicate = 12 GAT mutation. DxS: Rejected, control Ct > 35
67 ND ND Pyro: Failed, repeated in triplicate. DxS: Rejected, control Ct > 35
89 ND ND Pyro: Failed. DxS: Rejected, control Ct > 35
93 ND WT Pyro: Check, triplicate = inconclusive. DxS: triplicate = wt
100 12 GTT 12 GTT Pyro: Low mutation signal, triplicate = 12 GTT mutation. DxS: 12 GTT mutation
Summary of the mutational status of samples with “check”, “failed” (PyroMark) or “rejected” (TheraScreen, DxS) status. ND = mutation status could not be
determined.
1    2    3    4     5     6    7     8     9    10   11
100
200
400
bp
Figure 5 Multiplex PCR analysis of DNA fragmentation.D N A
size ladder (lane 1). DNA samples that in the PyroMark assay: failed
(lanes 2-4); had a “check” status (lanes 5-7); or “passed” (lanes 8-11).
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by Packham et al. [12]), we argue that codon 61 muta-
tions are more common than generally believed. The
reason for the low incidence of codon 61 mutations
reported in the Catalogue of somatic mutations in can-
cer database (0.3%) [2] and elsewhere (0-1.6%) [14-18]
might be due to the use of sub-optimal sequencing
methods or, simply, the widespread use of methods lim-
ited to codon 12 and 13 analysis. The clinical implica-
tion of KRAS codon 61 mutations in the treatment of
CRC patients with EGFR inhibitors is not fully under-
stood. However, a recent study indicates that codon 61
mutations are associated with resistance to cetuximab
treatment [20].
The analytical sensitivity and specificity to detect a
KRAS mutation in a clinical CRC sample will depend on
(i) the technical ability to detect mutated alleles in a
background of normal wt alleles, (ii) the sensitivity to
DNA degradation in terms of DNA template target
lengths, and (iii) the defined thresholds and signal
strengths required for a positive or negative mutation
call. The presence of normal cells, such as infiltrating
inflammatory cells and stromal cells, will reduce the
possibility to detect cancer-associated somatic mutations
in a tumor sample. In clinical practice, even after man-
ual microdissection, samples with a low tumor cell frac-
tion are relatively common. In our series 18% of the
samples had a final tumor cell content of < 10%. For
these samples direct Sanger sequencing will not be sen-
sitive enough as a tumor cell fraction of at least 25-30%
is believed to be required for mutation detection by this
method [25]. Hence, a more sensitive method is needed
for an accurate analysis of these samples. Previous stu-
dies using either in-house developed, or PyroMark v2.0,
Pyrosequencing assays have defined a detection limit of
5% mutant alleles [22,38]. According to the TheraScreen
(DxS) manual, this kit has a reported sensitivity of 1%
(of mutated alleles among wt alleles). This would corre-
spond to a tumor cell content of 2% when detecting a
heterozygote mutation in the tumor cells. Here we
report that a similar sensitivity can be reached using the
Pyrosequencing kit. We believe that the titration experi-
ment performed in this study, using tumor and normal
DNA from FFPE tissue, possibly better reflects the true
diagnostic situation compared to dilution experiments
with recombinant DNA or mixtures of non-fixed cul-
tured cell lines. However, we find that both assays are
sensitive to poor DNA quality. Indeed, DNA fragmenta-
tion induced by formalin fixation and/or degradation
due to necrosis will reduce the success rate of PCR
amplification, and might potentially introduce mutation
artefacts [39,40].
In a blinded sub-study of 100 CRC samples, we com-
pared the two CE-marked mutation detection kits,
PyroMark KRAS and TheraScreen K-RAS mutation kit,
by adhering to the manufacturers’ protocols and guide-
lines for interpretation of the results. The mutational sta-
tus could be defined for 94 and 91 samples, respectively,
and both assays detected the same number of mutated
samples. After analysis of DNA fragmentation, we con-
cluded that suboptimal DNA quality was the reason that
some samples did not pass the quality thresholds. Analy-
sis of such samples resulted in a high control Ct (Ther-
aScreen) or low signal strength (PyroMark). Both assays
uncovered identical mutations in 32 of the samples. In
addition, one sample that was rejected in the TheraSc-
reen assay was found KRAS m u t a t e dw h e na n a l y s e dw i t h
the PyroMark assay. Conversely, a mutation defined by
the TheraScreen assay in one sample could not be exclu-
sively confirmed by the PyroMark assay. Our experience
when comparing the two assays in clinical practice is that
the TheraScreen assay is possibly slightly more sensitive
in terms of detecting low numbers of mutated alleles.
However, as this assay is dependent on several real-time
PCR reactions in combination with a strict regulatory
definition of true mutations and thresholds for rejection
(in terms of Ct values), this assay seems to be more
dependent on high DNA quality in comparison to the
PyroMark assay. Moreover, less DNA is needed for the
PyroMark assay (10 ng) in comparison with the TheraSc-
reen method (8×2-20 ng). The amount of DNA required
for a mutation analysis can be of importance when ana-
lysing minimal colonoscopy fragments or core needle
biopsies. Similar to our DxS TheraScreen results, a failure
rate of 5-10% have been reported when analysing CRC
samples for KRAS mutations using the DxS technology.
The failed samples either had limited material or poor
quality of the DNA [41,42]. In comparison, when ana-
lysed with Pyrosequencing, the failure rate was 2.5% for
t h e3 1 4c o n s e c u t i v eC R Cs a m p l e si nt h i ss t u d y .F i n a l l y ,
we want to emphasise that the criteria for “mutations” or
“rejections”, as defined by manufacturers of kits, or indi-
vidual molecular pathology laboratories, adds a subjective
dimension to the interpretation of the results that goes
beyond a pure technical comparison of different assays.
Conclusions
Our conclusion from the KRAS analysis of the 314 clini-
cal samples together with data from the comparison of
the two CE-marked assays is that both assays are well
suited for KRAS mutation analysis of DNA from FFPE
CRC samples. Both assays have a sufficient analytical
sensitivity to efficiently detect KRAS mutations even in
samples with < 10% tumor cells.
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